Biology subjects

Tarantino, G.

Publications and source records attributed to Tarantino, G..

9 recordsLinked to original sources

bioRxiv2026

Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in BRAF-Mutant Melanoma

BRAF-targeted therapy (BRAFi/MEKi) and immune checkpoint blockade (anti-PD-1/anti-CTLA-4) have transformed the treatment of BRAF-mutant metastatic melanoma. While most patients who respond to targeted therapy eventually progress, a subset derives durable benefit, and biomarkers to identify this subset would inform optimal treatment selection. In this study, we analyzed pre-treatment tumor samples from a clinically annotated cohort of 155 patients with BRAF-mutant metastatic melanoma treated with first-line BRAFi/MEKi and followed for up to five years. We stratified patients into durable responders (PFS [≥] 24 months) and rapid progressors (PFS < 6 months with progression) and found that a global metric of tumor genomic heterogeneity, rather than individual gene alterations, distinguished these groups. Combining genomic heterogeneity with baseline tumor burden (e.g., lactate dehydrogenase (LDH) or radiographic lesion dimensions), we developed a parsimonious model that predicted durable responders with high precision and specificity. Notably, the analogous population of patients treated instead with immunotherapy were not durable responders, suggesting that the selected predictors of durable responders are targeted therapy specific. Spatial profiling of a subset of pre-treatment biopsies (n = 47) demonstrated that high intratumoral, but not peritumoral, CD8+ T-cell infiltration correlated with prolonged survival on BRAF-targeted therapy and served as an independent predictive factor when considered with genomic heterogeneity and features of clinical tumor burden. Together, these findings highlight the distinct baseline intrinsic and extrinsic features underlying durable response to BRAF-targeted therapy and support their potential implication in guiding treatment selection for patients with BRAF-mutant metastatic melanoma. One-Sentence SummaryIntegrated clinical, tumor genomic, and immune microenvironmental features predict durable responses to BRAF-targeted therapy.

cancer biology↗

bioRxiv2026

Expanding P-NET, a multi-purpose biologically informed deep learning framework

We present expanded P-NET, a versatile frame-work for deep learning in computational biology based on P-NET, leveraging biological pathways for interpretable predictions. Our framework achieves competitive performance in genomic & transcriptomic prediction tasks. We demonstrate its stability and interpretability compared to traditional machine learning models. P-NET 2.0 incorporates gene and pathway information, providing valuable insights into complex biological processes. The framework is publicly available, enabling its application to various computational biology tasks.

bioinformatics↗

bioRxiv2025

Multiomic profiling of a unique in-transit melanoma cohort identifies melanoma differentiation as predictor of tumor progression and therapy response

Melanoma patients with in-transit metastasis (ITM), a stage of disease where melanoma has metastasized to sites in between the primary lesion and draining lymph node, vary significantly in their clinical outcomes, but the biology driving differential outcomes in ITM is poorly understood. To elucidate the mechanisms of differential outcomes, we utilized multimodal molecular profiling (WES, RNA-seq, highly multiplexed immunofluorescence, spatial transcriptomics) in 1) evolutionary analysis of longitudinal tumor samples and 2) identifying prognostic tumor intrinsic and microenvironmental features in a unique cohort of patients with unresectable ITM. Among other findings, we observed a persistent dedifferentiated AXL/NGFR clonal lineage pre-existing and following immune checkpoint blockade in in-transit and distant metastases. Concordantly, we found that low pigmentation and high T cell exhaustion signatures were independently associated with distant progression. Our findings highlight tumor cell state and immune dysfunction as key predictors and potential biomarkers of metastatic risk in ITM. STATEMENT OF SIGNIFICANCEWhat drives distant progression in melanoma is unclear. Analyzing tumor and immune features in a rare in-transit melanoma patient cohort, we identify biological signals highlighting how immune and tumor states observable in pre-distant metastasis melanomas shape long-term outcomes, and nominate potential prognostic biomarkers.

cancer biology↗

bioRxiv2025

The systemic JIA synovial fluid environment supports development and prevalence of specific inflammatory T helper cell phenotypes

ObjectiveThe potential involvement of adaptive immunity in systemic juvenile idiopathic arthritis (sJIA) pathophysiology remains an intriguing question. Here, we investigated whether and how the inflammatory environment in sJIA versus JIA synovial fluid (SF) may differentially impact T helper (Th) cell polarization and activation. MethodsSF samples from sJIA and JIA patients (both n=7) were tested in various cell culture setups, with or without recombinant cytokines or cytokine-blocking drugs, to assess their effects on healthy donor Th cell activation. We analyzed cellular surface marker, transcription factor, and effector molecule expression using flow cytometry, Luminex, ELISA, and qRT-PCR. ResultsBoth sJIA and JIA SF revealed highly pro-inflammatory profiles. Compared to JIA, sJIA SF demonstrated markedly elevated IL-1{beta}, IL-18, GM-CSF, S100A9, and MPO levels, while JIA SF showed trends toward higher soluble FasL and IL-17A concentrations. Notably, sJIA SF significantly increased CD4 T cell ICOS expression and expanded CXCR3posCCR6pos Th cells, whereas JIA SF favored expansion of CXCR3negCCR6pos Th cells and CCR6pos Th cell expansion was sensitive to IL-1 blockade. Systemic JIA SF selectively sustained a IFN{gamma}/IL-21 expressing T peripheral helper (Tph) phenotype, particularly associated with IL-1{beta}, IL-18, and GM-CSF SF levels. Spiking JIA SF with a cocktail of these cytokines recapitulated some T cellular phenotypic features observed in sJIA SF cultures. ConclusionJIA and sJIA SF drive distinct Th cell polarization, including differential and sustained Tf/ph cell activation. These findings complement our earlier observations in sJIA peripheral blood and demonstrate the impact of the SF inflammatory matrix on immune cell activation. What is already known on this topicO_LISystemic juvenile idiopathic arthritis (sJIA, Stills Disease) is initially hallmarked by innate immunity driving systemic inflammation C_LIO_LIWith further disease course sJIA can progress to chronic destructive arthritis with several studies suggesting an involvement of adaptive immunity in this process. C_LIO_LIIn a previous study we linked T follicular/peripheral helper (Tfh/Tph) cells in sJIA patients blood to arthritis and self-reactive antibody signatures in patients with longer disease duration C_LI What this study addsO_LIOur study demonstrates that sJIA versus JIA synovial fluid (SF) can drive differential T helper cell (Th cell) polarization and activation. C_LIO_LIOur data imply that sJIA SF promotes the self-sustenance of Th cells with a Tph phenotype characterized by IFN{gamma}, IL-21 and c-MAF expression. C_LIO_LIIL-1{beta}, IL-18, and GM-CSF levels in sJIA SF can be associated with Tph perseverance, and recapitulate sJIA Tph features when spiked into JIA SF. C_LI How this study might affect research, practice or policyO_LIThe present data complement our earlier observations from sJIA peripheral blood and strengthen the biphasic model hypothesis regarding sJIA progression C_LIO_LIWhile both JIA and sJIA patients can develop clinically similar arthritis, our data demonstrate how the respective local inflammatory environments can differentially impact and shape T cell immunity. C_LIO_LIOur data suggest a combined and early targeting of both IL-1{beta} and IL-18 in sJIA may be effective in preventing the generation of inflammatory T cell subsets with the potential to drive chronic arthritis through a joint-localized, adaptive immune response. C_LI

immunology↗

bioRxiv2025

Clinico-genomic features predict distinct metastatic phenotypes in cutaneous melanoma

Metastasis drives mortality and morbidity in cancer. While some patients develop broad metastatic disease across multiple organs, others exhibit organ-specific spread. To identify mechanisms underlying metastatic organotropism, we analyzed clinico-genomic data from over 7,000 patients with metastatic cutaneous melanoma in three independent cohorts (one primary discovery and two validation cohorts including a nationwide electronic health record-derived deidentified database), leveraging machine learning approaches to clinical data. We found that female sex and increased tumor mutational burden associate with decreased metastatic potential, while older age associates with increased lung and adrenal metastases. Using unsupervised analyses, patients clustered into five metastatic patterns: a "highly metastatic" cluster characterized by involvement of many organs, a "low metastatic" cluster characterized by few metastatic sites (mostly lymph node metastases), and three additional clusters each characterized by metastasis to specific sites (brain, lung, liver). Mutations in B2M and PTEN associated with increased overall metastatic potential. PTEN mutations were also associated with brain metastases but were enriched only in the "highly metastatic" cluster and not the brain-specific cluster. Mutations in GNAQ or GNA11 (GNA) associated with increased liver metastasis. To validate this association, we tested and demonstrated liver tropism in two GNA-mutant genetically engineered cutaneous melanoma mouse models of metastasis. Overall, our study elucidates distinct phenotypes of metastasis in patients with melanoma and identifies novel clinical and genomic associations that illuminate the drivers of clinical metastatic organotropism.

cancer biology↗

bioRxiv2024

Stratified analysis identifies HIF-2α as a therapeutic target for highly immune-infiltrated melanomas

While immune-checkpoint blockade (ICB) has revolutionized treatment of metastatic melanoma over the last decade, the identification of broadly applicable robust biomarkers has been challenging, driven in large part by the heterogeneity of ICB regimens and patient and tumor characteristics. To disentangle these features, we performed a standardized meta-analysis of eight cohorts of patients treated with anti-PD-1 (n=290), anti-CTLA-4 (n=175), and combination anti-PD-1/anti-CTLA-4 (n=51) with RNA sequencing of pre-treatment tumor and clinical annotations. Stratifying by immune-high vs -low tumors, we found that surprisingly, high immune infiltrate was a biomarker for response to combination ICB, but not anti-PD-1 alone. Additionally, hypoxia-related signatures were associated with non-response to anti-PD-1, but only amongst immune infiltrate-high melanomas. In a cohort of scRNA-seq of patients with metastatic melanoma, hypoxia also correlated with immunosuppression and changes in tumor-stromal communication in the tumor microenvironment (TME). Clinically actionable targets of hypoxia signaling were also uniquely expressed across different cell types. We focused on one such target, HIF-2, which was specifically upregulated in endothelial cells and fibroblasts but not in immune cells or tumor cells. HIF-2 inhibition, in combination with anti-PD-1, enhanced tumor growth control in pre-clinical models, but only in a more immune-infiltrated melanoma model. Our work demonstrates how careful stratification by clinical and molecular characteristics can be leveraged to derive meaningful biological insights and lead to the rational discovery of novel clinical targets for combination therapy.

cancer biology↗

bioRxiv2022

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma

While the introduction of immune checkpoint blockade (ICB) has dramatically improved clinical outcomes for patients with advanced melanoma, a significant proportion of patients develop resistance to therapy, and mechanisms of resistance are poorly elucidated in most cases. Further, while combination ICB has higher response rates and improved progression free survival compared to single agent therapy in the front line setting, there is significantly increased toxicity with combination ICB, and biomarkers to identify patients who would disproportionately benefit from combination therapy vs aPD-1 ICB are poorly characterized. To understand resistance mechanisms to single vs combination ICB therapy, we analyze whole-exome-sequencing (WES) of pre-treatment tumor and matched normals of 4 cohorts (n=140) of previously ICB-naive aPD-1 ICB treated patients. We find that high intratumoral genomic heterogeneity and low ploidy identify patients with intrinsic resistance to aPD-1 ICB. Comparing to a melanoma cohort from a pre-targeted therapy and ICB time period ("untreated" cohort), we find that genomic heterogeneity specifically predicts response and survival in the ICB treated cohorts, but not in the untreated cohort, while ploidy is also prognostic of overall survival in the "untreated" (by targeted therapy or ICB) group. To establish clinically actionable predictions, we optimize a simple decision tree using genomic ploidy and heterogeneity to identify with high confidence (90% PPV) a subset of patients with intrinsic resistance to and significantly worse survival on aPD1 ICB treatment. We then validate this model in independent cohorts, and further show that a significant proportion of patients predicted to have intrinsic resistance to single agent aPD-1 ICB respond to combination ICB, which suggests that nominated patients may benefit disproportionately from combination ICB. We further show that the features and predictions of the model are independent of known clinical features and previously nominated molecular biomarkers. These findings highlight the clinical and biological importance of genomic heterogeneity and ploidy, and sets a concrete framework towards clinical actionability, broadly advancing precision medicine in oncology.

cancer biology↗

bioRxiv2022

Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy Resistance

Immune checkpoint blockade (ICB) therapy has improved long-term survival for patients with advanced melanoma. However, there is critical need to identify potential biomarkers of response and actionable strategies to improve response rates. Through generation and analysis of 148 chromatin modification maps for 36 melanoma samples from patients treated with anti-PD- 1, we identified significant enrichment of active enhancer states in non-responders at baseline. Analysis of an independent cohort of 20 samples identified a set of 437 enhancers that predicted response to anti-PD-1 therapy (Area Under the Curve of 0.8417). The activated non-responder enhancers marked a group of key regulators of several pathways in melanoma cells (including c- MET, TGF{beta}, EMT and AKT) that are known to mediate resistance to ICB therapy and several checkpoint receptors in T cells. Epigenetic editing experiments implicated involvement of c-MET enhancers in the modulation of immune response. Finally, inhibition of enhancers and repression of these pathways using bromodomain inhibitors along with anti-PD-1 therapy significantly decreased melanoma tumor burden and increased T-cell infiltration. Together, these findings identify a potential enhancer-based biomarker of resistance to anti-PD-1 and suggest enhancer blockade in combination with ICB as a potential strategy to improve responses.

cancer biology↗

bioRxiv2018

Interferon-alpha2 but not interferon-gamma serum levels are associated with intramuscular fat in obese patients with nonalcoholic fatty liver disease

BackgroundIntramuscular triglycerides (IMTGs) represent an important energy supply and a dynamic fat-storage depot that can expand during periods of elevated lipid availability and a fatty ac-id source. Ultrasonography (US) of human skeletal muscles is a practical and reproducible method to assess both IMTG presence and entity.\n\nAlthough a crosstalk between cytokines in skeletal muscle and adipose tissue has been suggested in obesity, condition leading to hepatic steatosis (HS) or better defined as nonalcoholic fatty liver disease and cancer, there are still questions to be answered about the role of interferons (IFNs), alpha as well as gamma, and IMTG in obesity. We aimed at discovering any correlation between IFNs and IMTG.\n\nMethodsWe analysed anthropometric data, metabolic parameters and imaging features of a population of obese subjects with low-prevalence of co-morbidities but HS. The levels of serum IFNs were detected by a magnetic bead-based multiplex immunoassays.\n\nResultsSerum concentrations of IFN-alpha2 were increased, while serum levels of IFN-gamma were decreased confronted with those of controls; the severity of IMTG, revealed at US as Heckmatt scores, was inversely predicted by IFN-alpha2 serum concentrations; IMTG scores were not predicted by serum levels of IFN-gamma; IMTG scores were predicted by HS severity, ascertained at US; HS severity was predicted by visceral adipose tissue, assessed by US, but the latter was not instrumental to IMTG.\n\nDiscussion & ConclusionThis study has added some pieces of observation about the cytokine network regulating the interplay between IMTG and obesity in obese patients with HS.

epidemiology↗